Abstract: The present disclosure relates to a plurality of host materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising the specific combination of the compounds according to the present disclosure as a plurality of host materials, or by comprising the compound according to the present disclosure, an organic electroluminescent device with low driving voltage and/or long lifespan characteristics can be provided, compared to a conventional organic electroluminescent device.

Abstract: The present invention relates to a prebiotic composition, a composition for improving gut microorganisms, a composition for improving gut health or gut function, a composition for alleviating, preventing, or treating inflammatory bowel disease or leaky gut syndrome, or a composition for alleviating, preventing, or treating obesity or metabolic disease, which each comprise a molokhia extract or a molokhia polymer fraction as an active ingredient to induce the proliferation of beneficial intestinal bacteria and to improve, prevent, or treat gut heath or gut function. In addition, the composition comprising a molokhia extract or a molokhia polymer fraction as an active ingredient can alleviate, prevent, or treat bowel disease or leaky gut syndrome.

Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.

Abstract: A semiconductor package and a method of manufacturing a semiconductor package. As a non-limiting example, various aspects of this disclosure provide a semiconductor package, and method of manufacturing thereof, that comprises shielding on multiple sides thereof.

Abstract: Proposed are a coordination complex compound-ZIF complex and a method of preparing the same. More particularly, proposed are a coordination complex compound-ZIF complex, which is a complex on which a coordination complex compound is supported by being chemically and directly bonded to a metal vacancy site of a ZIF, capable of being usable as a heterogeneous catalyst that can be recovered and reused in subsequent processes and maintaining catalytic functions of the coordination complex compound, which is an active ingredient, and to a method of preparing the same.

Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.

Abstract: Provided are a sheet, a method of its preparation, and a tire comprising the sheet, wherein the sheet comprises tire cords, a topping rubber for topping the tire cords, and a conductive fiber located on the surface of the topping rubber. The sheet can provide tires, on which a rubber composition with a low electricity-transmitting property and low rolling resistance is applied, with excellent conductivity.

Abstract: The present invention relates to a tire including a fabric strip, and the tire includes a fabric strip in a belt layer, the fabric strip including a plurality of warps arranged in parallel to one another and wefts arranged to weave the warps. The tire according to the invention is advantageous in that the production process is simplified, the production cost required during the production process is lowered, the weight of the tire is reduced, and the fuel efficiency is increased when a car using the tire of the invention is driven, by reducing the resistance to rolling.

Abstract: Disclosed are a compound represented by Formula (1) below, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R3,and Xi to X6 are the same as defined in claim 1.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: Provided are a sheet, a method of its preparation, and a tire comprising the sheet, wherein the sheet comprises tire cords, a topping rubber for topping the tire cords, and a conductive fiber located on the surface of the topping rubber. The sheet can provide tires, on which a rubber composition with a low electricity-transmitting property and low rolling resistance is applied, with excellent conductivity.

Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Abstract: Provided are a touch panel, a method of manufacturing the same, and a touch panel integrated organic light emitting display device. The touch panel includes a substrate, a plurality of connection electrodes, an over-coating layer, a first line electrode, a second line electrode, a plurality of first segment electrodes, and a plurality of second segment electrodes. The plurality of connection electrodes is disposed on the substrate to be separated from each other. The over-coating layer includes a plurality of contact holes exposing a part of each connection electrode. The second line electrode is connected with the connection electrode through the contact hole of the over-coating layer without disconnection.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.

Abstract: A hybrid cord for a tire, a method of manufacturing the same, and a high-performance environment-friendly radial tire including the same are disclosed herein. The hybrid cord includes a high-modulus fiber ply and a low-modulus fiber ply. The hybrid cord has a stress-strain curve including an initial modulus section, an intermediate modulus section and a final modulus section. The initial modulus of the initial modulus section is higher than the intermediate modulus of the intermediate modulus section, and the final modulus of the final modulus section is higher than the intermediate modulus.

Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.

Abstract: A refrigerator includes a mid-frame positioned on a front surface of the main body wall and a heater configured to heat the mid-frame and provided at the mid-frame. The mid-frame includes a front frame provided to cover at least a part of a front surface of the at least one inner box configured to form the main body wall, and an extension frame formed to extend rearward from the front frame and including an edge portion in which an end portion of the extension frame has a thickness greater than that of an adjacent extension frame.

Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.

Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.